Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Secures $10M in Revolving Credit

NEW YORK, Dec. 27 - Orchid BioSciences said today it obtained a $10 million revolving line of credit based on accounts receivable.


The credit line is from Comerica, a bank based in Detroit.


Financial details of the agreement were not disclosed.


"This credit facility provides Orchid with a cost-effective, flexible resource to help us meet our working capital needs as we progress towards profitability in 2003," Andrew Savadelis, Orchid CFO, said in a statement.


Orchid had reported it had around $8.5 million in cash and cash equivalents, another $609,000 in short-term investments, and just over $1 million in restricted cash as of Sept. 30. In November, the company said it was selling off its Life Sciences business to focus its resources on gene profiling.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.